Science Daily

Successful therapy confirmed for newborns with the fatal metabolic disorder MoCD type A

Early administration of the drug Fosdenopterin/rcPMP improves the chances of survival of infants with MoCD type A and promotes the development of brain functions. The drug fosdenopterin/rcPMP ...
technologynetworks

Therapy for Newborns With MoCD Type A Shows Promising Clinical Trial Results

The drug fosdenopterin/rcPMP considerably improves the chances of survival and developmental progress in infants with molybdenum cofactor deficiency (MoCD type A), a ...
Yahoo Finance

BridgeBio Pharma and Affiliate Origin Biosciences Announce FDA Approval of NULIBRY™ (fosdenopterin), the First and Only Approved Therapy to Reduce the Risk of Mortality in ...

PALO ALTO, Calif., Feb. 28, 2021 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio) and affiliate Origin Biosciences, Inc. (Origin) today announced the U.S. Food and Drug ...
Yahoo Finance

BridgeBio Pharma and Sentynl Therapeutics Receive Marketing Authorization in the EU for NULIBRY® (fosdenopterin) for the Treatment of MoCD Type A

PALO ALTO, Calif. and SOLANA BEACH, Calif. and AHMEDABAD, India, Sept. 20, 2022 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio), a commercial-stage biopharmaceutical company that ...
MedCity News

BridgeBio turns Alexion asset into first approved drug for rare metabolic disease

The drug, fosdenopterin, is a treatment for molybdenum cofactor deficiency (MoCD) type A. Babies born with this disease experience a rapid progression of neurological problems including seizures, ...
Nasdaq

BridgeBio Pharma’s Origin Biosciences Enters Partnership With Medison to Commercialize BBP-870 in Israel for MoCD Type A

BOSTON, Dec. 18, 2019 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) subsidiary Origin Biosciences, a company focused on developing and commercializing a treatment for Molybdenum Cofactor ...